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Letter to the Editor
Viral Load for HIV Treatment Failure Management: A Report of Eight Drug-Resistant
Tuberculosis Cases Co-Infected with HIV Requiring Second-Line Antiretroviral
Treatment in Mumbai, India
Dear Sir:
We read with great interest the report by Satti H,
McLaughlin MM, and Seung KJ describing six HIV/drug-
resistant tuberculosis (HIV/DR-TB) co-infected patients who
failed first-line antiretroviral treatment (ART) in Lesotho.1
We would like to share an experience treating similar patients
in Mumbai, India. Although having a lower HIV prevalence
compared with many African countries, India has the third
largest population living with HIV, after South Africa and
Nigeria, with an estimated 2,090,000 people affected in 2011.2
Furthermore, India has the highest burden of TB in the
world, representing one-fifth (21%) of the global incidence.
Unfortunately, India does not have national data on DR-TB
prevalence, but a survey conducted in the States of Gujarat
and Maharashtra in 2007 estimated the prevalence of DR-TB
to be 3% in new cases and 12–17% in retreatment cases.3
Between October 2006 and July 2013, Me´decins Sans
Frontie`res (MSF) treated 129 DR-TB patients co-infected
with HIV at a clinic in Mumbai. The patients were referred
to us from government ART centers, public-private ART
centers, and a network of community non-governmental
organizations. All HIV patients were monitored with viral
load (VL) testing at least every 6 months, as recommended
by Satti. Patients identified as having virological failure
received adherence counseling and subsequently had the
VL test rechecked at 3–6 months. Those in whom the VL
test did not re-suppress were switched to a second-line ART
regimen consisting of a protease inhibitor (PI) and suitable
nucleoside(tide) reverse transcriptase inhibitors (NRTIs),
based on genotype HIV resistance testing when necessary.
Of the 129 DR-TB patients co-infected with HIV, 8 patients
required second-line ART4; the median baseline CD4 count
of the 8 patients before DR-TB treatment initiation was
102.5 cells/mL. Three of the 8 patients were on first-line ART
at the time of DR-TB treatment initiation and had to be
switched to second-line ART during the course of DR-TB
treatment (Table 1). All 3 had a VL result > 5,000 copies/mL
before the switch; subsequent VL testing showed a 2-log
decrease in the two patients in whom a result was available.
In the six patients having a CD4 count available at the
end of DR-TB treatment, five had an increase compared
with baseline. Five out of eight patients had successful out-
comes: 3 were cured and 2 successfully completed DR-TB
treatment. Two patients were unfortunately lost to follow-up,
and there was one death (Case 5). In this latter case, there
was extensive pulmonary involvement and additional resis-
tance of the TB strain to fluoroquinolones.
We agree with the recommendation of Satti that VL test-
ing be performed routinely in DR-TB patients co-infected
with HIV. It allows for early detection of ART adherence
problems, which has been shown in other reports to pre-
vent an unnecessary switch to a second-line regimen with
enhanced adherence support.5 In those in whom the VL
result cannot be re-suppressed (i.e. caused by development of
HIV drug resistance), an early switch to a second-line regimen
is likely to increase the chances of a more successful outcome.
We would like to reinforce an additional point that was implied
in their Short Report, that DR-TB and HIV management be
integrated in co-infected patients. Such patients are compli-
cated and ideally should be managed in the same health facility
by the same team of health care providers.
At present, HIV VL testing is reserved only for sus-
pected cases of treatment failure attending public ART
centers in Mumbai and is not used for routine monitoring.
Such an approach is likely to delay early detection of ART
failure and contribute to the poor outcomes being seen in
DR-TB patients co-infected with HIV.6 In this and other
national HIV/ART programs not yet implementing routine
VL testing, we ask that this be prioritized in HIV patients
being treated for DR-TB. We also hope to see stronger col-
laboration between all HIV/ART and DR-TB programs with
Table 1
CD4 count, viral load, and TB treatment response of patients on second-line ART
Case Age/sex
TB resistance
pattern
Baseline
CD4 count
ART regimen
CD4 count
at the end
of DR-TB
treatment
Time to
TB culture
conversion
(months)
Present
outcomeAt initiation of DR-TB treatment
Switch to second-line
ART during
DR-TB treatment
1. 34/Male MDR PTB 62 TDF, AZT, 3TC, LPV/r (second-line) N/A 256 6 Cured
2. 39/Male MDR PTB 95 AZT, 3TC, LPV/r (second-line) N/A N/A No conversion Lost to
follow-up
3. 40/Male MDR EPTB 97 D4T, 3TC, EFV (first-line) TDF, 3TC, LPV/r 137 3 Completed
4. 47/Male MDR PTB 32 TDF, 3TC, LPV/r (second-line) N/A 147 2 Cured
5. 37/Female Pre-XDR PTB 165 D4T, 3TC, EFV (first-line) ABC, 3TC, ATV/r 127 24 Died
6. 50/Male MDR EPTB 108 AZT, 3TC, EFV (first-line) TDF, 3TC, LPV/r N/A N/A Lost to
follow-up
7. 52/Male MDR PTB 122 D4T, 3TC, LPV/r (second-line) N/A 437 2 Cured
8. 51/Male MDR EPTB 161 TDF, AZT, 3TC, LPV/r (second-line) N/A 211 N/A (empiric
DR-TB
treatment)
Completed
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a view toward eventual integration of services for these com-
plicated patients, to allow for better management.7
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